IP Verse

Arena Pharmaceuticals, Inc. opposition analysis

COMPANY ANALYSIS

Latest patents of Arena Pharmaceuticals, Inc. opposed by its competitors

Patent:

EP3860590

Grant Date:

Jun 7, 2023

Title:

Methods For The Treatment Of Scleroderma

Oppositions:

Patent:

EP3310760

Grant Date:

Oct 19, 2022

Title:

Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders

Oppositions:

Latest patents of Arena Pharmaceuticals, Inc. opposed by its competitors

Patent Number	Grant Date	Title	Total Oppositions
EP3860590	Jun 7, 2023	Methods For The Treatment Of Scleroderma	2
EP3310760	Oct 19, 2022	Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders	2

Competitors of Arena Pharmaceuticals, Inc.

HAMM&WITTKOPP PATENTANWALTE PARTMBB

SANDOZ AG

SCORPIO IP LIMITED

Want to track Arena Pharmaceuticals, Inc.?

Feel free to send us a message here and we will get back to you